Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Operating Expenses (2019 - 2025)

Biodesix's Operating Expenses history spans 7 years, with the latest figure at $30.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 69.46% year-over-year to $30.7 million; the TTM value through Dec 2025 reached $61.0 million, down 53.48%, while the annual FY2025 figure was $116.4 million, 9.97% up from the prior year.
  • Operating Expenses reached $30.7 million in Q4 2025 per BDSX's latest filing, up from $1.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $100.6 million in Q4 2024 to a low of -$60.5 million in Q4 2023.
  • Average Operating Expenses over 5 years is $19.2 million, with a median of $22.1 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: crashed 357.57% in 2023, then surged 1595.49% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $18.9 million in 2021, then grew by 24.3% to $23.5 million in 2022, then plummeted by 357.57% to -$60.5 million in 2023, then skyrocketed by 266.24% to $100.6 million in 2024, then tumbled by 69.46% to $30.7 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Operating Expenses are $30.7 million (Q4 2025), $1.3 million (Q3 2025), and $1.9 million (Q2 2025).